PURPOSE: To evaluate the impact of timing of blood transfusion in patients with upper tract urothelial carcinoma (UTUC) treated with radical nephroureterectomy (RNU). METHODS: Outcomes of consecutive patients with UTUC treated with RNU were analyzed. Clinicopathologic factors were compared using Fisher's exact test or the Wilcoxon rank-sum test between patients who received any transfusion and no transfusion, and between patients receiving intraoperative transfusion only and patients receiving no transfusion. Cancer-specific and overall survival were estimated and multivariable analyses were performed to assess the impact of timing of transfusion on clinical outcomes. RESULTS: Among 402 patients included in this study, 71 (17.6%) patients received a transfusion at any point and 27 (6.7%) patients received an intraoperative blood transfusion. Transfusion at any time, patient comorbidity, high grade, advanced stage, positive surgical margins, low preoperative hemoglobin, longer operative duration, and increased blood loss were significantly associated with cancer-specific survival (DSS) on univariable analysis (HR 1.85, 95% CI 1.20-2.85, p < 0.005). In the multivariable analysis, transfusion at any point was not a prognostic factor (HR 1.00, 95% CI 0.60-1.68, p = 0.99). When examining intraoperatively transfusion only, transfusion was significantly associated with DSS (HR 1.91, 95% CI 1.01-3.59, p = 0.045) but no longer significant in multivariable analysis (HR 0.72, 95% CI 0.32-1.65, p = 0.440). CONCLUSIONS: Our study indicates that the administration of blood transfusion either intraoperatively or postoperatively is not associated with clinical or oncological outcomes in patients with upper tract urothelial carcinoma when adjusted for other factors in multivariable analysis. Further study is required.
PURPOSE: To evaluate the impact of timing of blood transfusion in patients with upper tract urothelial carcinoma (UTUC) treated with radical nephroureterectomy (RNU). METHODS: Outcomes of consecutive patients with UTUC treated with RNU were analyzed. Clinicopathologic factors were compared using Fisher's exact test or the Wilcoxon rank-sum test between patients who received any transfusion and no transfusion, and between patients receiving intraoperative transfusion only and patients receiving no transfusion. Cancer-specific and overall survival were estimated and multivariable analyses were performed to assess the impact of timing of transfusion on clinical outcomes. RESULTS: Among 402 patients included in this study, 71 (17.6%) patients received a transfusion at any point and 27 (6.7%) patients received an intraoperative blood transfusion. Transfusion at any time, patient comorbidity, high grade, advanced stage, positive surgical margins, low preoperative hemoglobin, longer operative duration, and increased blood loss were significantly associated with cancer-specific survival (DSS) on univariable analysis (HR 1.85, 95% CI 1.20-2.85, p < 0.005). In the multivariable analysis, transfusion at any point was not a prognostic factor (HR 1.00, 95% CI 0.60-1.68, p = 0.99). When examining intraoperatively transfusion only, transfusion was significantly associated with DSS (HR 1.91, 95% CI 1.01-3.59, p = 0.045) but no longer significant in multivariable analysis (HR 0.72, 95% CI 0.32-1.65, p = 0.440). CONCLUSIONS: Our study indicates that the administration of blood transfusion either intraoperatively or postoperatively is not associated with clinical or oncological outcomes in patients with upper tract urothelial carcinoma when adjusted for other factors in multivariable analysis. Further study is required.
Authors: Thomas Seisen; Ross E Krasnow; Joaquim Bellmunt; Morgan Rouprêt; Jeffrey J Leow; Stuart R Lipsitz; Malte W Vetterlein; Mark A Preston; Nawar Hanna; Adam S Kibel; Maxine Sun; Toni K Choueiri; Quoc-Dien Trinh; Steven L Chang Journal: J Clin Oncol Date: 2017-01-03 Impact factor: 44.544
Authors: M Rieken; T Schubert; E Xylinas; L Kluth; M Rouprêt; Q-D Trinh; R K Lee; B Al Hussein Al Awamlh; H Fajkovic; G Novara; V Margulis; Y Lotan; J I Martinez-Salamanca; K Matsumoto; C Seitz; M Remzi; P I Karakiewicz; D S Scherr; A Briganti; A Bachmann; S F Shariat Journal: Eur J Surg Oncol Date: 2014-04-13 Impact factor: 4.424
Authors: Todd M Morgan; Daniel A Barocas; Sam S Chang; Sharon E Phillips; Shady Salem; Peter E Clark; David F Penson; Joseph A Smith; Michael S Cookson Journal: Urol Oncol Date: 2011-09-09 Impact factor: 3.498
Authors: Laura-Maria Krabbe; Mary E Westerman; Aditya Bagrodia; Bishoy A Gayed; Dina Khalil; Payal Kapur; Shahrokh F Shariat; Ganesh V Raj; Arthur I Sagalowsky; Jeffrey A Cadeddu; Yair Lotan; Vitaly Margulis Journal: Urol Oncol Date: 2014-01 Impact factor: 3.498
Authors: Mehrad Adibi; Ramy Youssef; Shahrokh F Shariat; Yair Lotan; Christopher G Wood; Arthur I Sagalowsky; Richard Zigeuner; Francesco Montorsi; Christian Bolenz; Vitaly Margulis Journal: Int J Urol Date: 2012-08-12 Impact factor: 3.369
Authors: Morgan Rouprêt; Vincent Hupertan; Thomas Seisen; Pierre Colin; Evanguelos Xylinas; David R Yates; Harun Fajkovic; Yair Lotan; Jay D Raman; Richard Zigeuner; Mesut Remzi; Christian Bolenz; Giacomo Novara; Wassim Kassouf; Adil Ouzzane; François Rozet; Olivier Cussenot; Juan I Martinez-Salamanca; Hans-Martin Fritsche; Thomas J Walton; Christopher G Wood; Karim Bensalah; Pierre I Karakiewicz; Francesco Montorsi; Vitaly Margulis; Shahrokh F Shariat Journal: J Urol Date: 2012-10-24 Impact factor: 7.450
Authors: E Jason Abel; Brian J Linder; Tyler M Bauman; Rebecca M Bauer; R Houston Thompson; Prabin Thapa; Octavia N Devon; Robert F Tarrell; Igor Frank; David F Jarrard; Tracy M Downs; Stephen A Boorjian Journal: Eur Urol Date: 2014-09-04 Impact factor: 20.096